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PRE-ECLAMPSIA AND ECLAMPLSIA MANAGEMENT IN NIGERIA 
Abstract:  Pre-eclampsia/eclampsia is the fourth most common cause of maternal 
mortality worldwide, affecting a disproportionate number of women in developing 
countries.  Nigeria has a maternal mortality ratio (MMR) of 840/100,000 live births and 
an estimated 10,000 women die from pre-eclampsia/eclampsia annually.  Magnesium 
Sulfate (MgSO4) is proven to reduce the likelihood that pre-eclampsia will progress to 
eclampsia by 58%, halt ecliptic seizures, and it is likely to reduce risk for maternal 
mortality related to this disease.  A review of the research of pre-eclampsia/eclampsia 
conducted in Nigeria reflects the gross underuse of MgSO4 as a life-saving therapeutic.  
Changes in current health policy are needed to improve antenatal care (ANC) services, 
provider education, and provision of essential medicines to improve maternal-fetal 
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PRE-ECLAMPSIA AND ECLAMPLSIA MANAGEMENT IN NIGERIA 
Problem statement and its relevance to Maternal and Child Health (MCH) 
  It is well documented that ninety-nine percent of the approximately 350,000 
maternal deaths occurring annually worldwide are in low-resourced, developing countries 
(World Health Organization, WHO, 2011).  Over half of the maternal mortality 
worldwide occurs in six countries: India, Nigeria, Pakistan, Afghanistan, Ethiopia, and 
Democratic Republic of the Congo (Hogan, et al., 2010).  The most common direct 
causes are post- partum hemorrhage (25%), sepsis (13%), unsafe abortions (13%), pre-
eclampsia and eclampsia (12%), and obstructed labor (8%).  Between 75 and 50 
thousand women are thought to die annually from complications resulting from pre-
eclampsia and eclampsia (Ridge, Bero & Hill, 2010; Tukur, 2009; WHO, 2011).  
Conversely, 3.3 million babies are stillborn annually and approximately 4 million die 
within the first 28 days of life (Hogberg, 2005).  814,000 neonatal deaths and 1.02 
million of these stillbirths are a result of intrapartum complications such as chronic 
oxygen deprivation (intrauterine hypoxia) and intrauterine growth restriction (IUGR) or 
other consequent sequelae, such as placenta abruption and poor fetal circulation. These 
pathological conditions directly result from pre-eclampsia and eclampsia (Turner, 2010; 
Wall et al., 2010).  Pre-eclampsia/eclampsia and uterine rupture are the two conditions 
which will most often result in the death of mother and baby, often called the double 
tragedy (Onwuhafua, 2002).  Improving health care services related to pre-eclampsia and 
eclampsia is in direct response to  the United Nations Millennium Development Goals 
(MDG) four and five, which aim to reduce rates of mortality for children (2/3 reduction) 
and mothers (3/4 reduction) by 2015 (UN Summit, 2000). 
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Pre-eclampsia and Eclampsia 
Pre-eclampsia and eclampsia are vascular, hypertensive disorders specific to 
pregnancy ranging in severity from mild to fatal.  There appears to be no preventive 
measures for this disease and etiology is variable and determined by gestational age at 
time of onset (Turner, 2010; Wall et al., 2010).  Time of onset is delineated as antepartum 
(after 20 weeks gestation), intrapartum (during the labor and delivery period) and 
postpartum (after the delivery of the baby).  The disease affects the placenta and maternal 
multiple-organ systems throughout its course.  It is also somewhat unpredictable in that 
pre-eclampsia is not necessarily a precursor to eclampsia, since about 25% of women will 
become eclamptic without first having pre-eclampsia symptoms (Duley, Henderson-
Smart, Walker, & Chou, 2010).  It is likely though that a pregnant woman with a pre-
eclampsia diagnosis will progress to eclampsia if left untreated.   
Pre-eclampsia is described as tissue edema and high blood pressure, categorized 
as a systolic blood pressure of >140 mmHg and diastolic blood pressure >90 mmHg, 
proteinuria (2+ or ≥300mg/24hr), and occurring after 20 weeks gestation, which are all 
likely to ultimately resolve for the mother at six weeks postpartum given the symptoms 
remain mild (Turner, 2010).  A recent review article published in the International 
Journal of Women‟s Health states disease severity can be determined by “blood pressure, 
liver dysfunction, and deteriorating neurological status” (Turner, 2010, p. 328).  
However, the WHO Safe Motherhood Guidelines set forth in 2008 identify proteinuria 
coupled with high blood pressure as diagnostic for pre-eclampsia after 20 weeks gestation 
(WHO, 2008).  For the fetus pre-eclampsia problems are evident with placental 
dysfunction and poor fetal circulation.  The placenta functions as the conduit for oxygen 
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and nutrients to the growing fetus.  Disturbance of adequate blood flow to the fetus 
through the placenta often leads to intrauterine growth restriction (IUGR) and a low birth 
weight baby.   
Severe pre-eclampsia is observed as systolic blood pressure ≥160mmhG and 
diastolic blood pressure ≥110 mmHg, nephrotic-range proteinuria (>3.5g/24hr), 
headache, visual disturbances, upper abdominal pain, oliguria (low urine output), hyper 
reflexia, pulmonary edema, and central nervous system and liver dysfunction (Turner, 
2010; WHO, 2008).  Also, it can cause placental abruption, when the placenta detaches 
form the uterine wall, and HELLP syndrome (hemolysis, elevated liver enzymes, and low 
platelets).  Placenta abruption requires careful monitoring and likely cesarean delivery if 
the mother and baby do not stabilize.  The characteristics of HELLP syndrome are 
enlarged liver, liver bleeding and elevated blood pressure. This condition is sometimes 
fatal and occurs in 10-20% of women who have severe pre-eclampsia or eclampsia 
(Sabai, 2007). 
Eclampsia is marked by the symptoms for severe pre-eclampsia with the addition 
of convulsive seizures, hemorrhage, and coma often leading to fatal maternal and 
neonatal outcomes.  As stated in the 2005 WHO midwifery education module “Managing 
eclampsia” the second and third stages of eclampsia are referred to as the tonic and clonic 
stages.  The tonic stage characteristics include violent muscle spasms, rigid limbs, 
decreased breathing, bulging eyes, an arched back and clenched teeth.  The clonic state 
refers to severe contraction and relaxation of muscles, foaming at the mouth, labored 
breathing and a swollen purplish face (WHO, 2008).  Likely, with the onset of eclampsia 
there is systemic capillary and vascular damage caused by high blood pressure.  Cerebral 
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edema results from an influx of red blood cells and blood plasma in the perivascular 
space in the brain tissue. This leads to ischemia (vascular blockage) and infarction in the 
brain, leading then to the neurological trauma and seizures (Okafur & Efetie, 2008).  
Delivery of the baby and the placenta is the only known effective treatment for life 
threatening severe pre-eclampsia and eclampsia (Churchill & Duley, 2002; Druzin, 
Charles, & Johnson, 2008).  Onset and progression of the disorder are highly variable 
thus consistent monitoring and therapeutic care of a patient suspected of having pre-
eclampsia or eclampsia are necessary to avoid poor outcomes.  
 
Significance of pre-eclampsia and eclampsia in Nigeria 
It is estimated that pre-eclampsia and eclampsia causes 10-15% of maternal 
morbidity in the developing world, and accounts for as much as 40% of maternal deaths 
in some countries (Turner, 2010;WHO, 2005).  Okafor and Efetie (2008) report 
eclampsia as the most common cause of maternal mortality in northern regions of 
Nigeria, which is known to be rural and isolated; and eclampsia contributes significantly 
to maternal demise in the southern region.  Nigeria has the highest population of African 
countries, with 158 million people (CIA World Factbook).  Nigerian women also suffer 
from the highest maternal mortality ratios (MMR), reported by the WHO in 2008 as 840 
maternal deaths per 100,000 live births, which is put into perspective when compared to 
the U.S. MMR of 24/100,000 live births.  In 2008 the neonatal mortality ratio (NMR) in 
Nigeria was 49/1000 live births (World Health Statistics, WHO 2010).  In the U.S. the 
NMR was approximately 4.5/1000 live births according to Center for Disease Control 
and Prevention and the U.S. Department of Health and Human Services. 
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Management of pre-eclampia and eclampsia 
The World Health Organization (WHO) has published guidelines and education 
modules for nurses and midwives for the immediate management of pre-eclampsia and 
eclampsia in under-resourced settings (WHO, 2005).  However, without adequate 
antenatal care (ANC) and early presentation at the onset of symptoms poor outcomes are 
likely.  Often the opportunity to provide anti-hypertension therapy is missed because of 
the lack of antenatal care or what is commonly referred to as the unbooked patient 
(Tukur, 2009).  The unbooked patient has no formal medical home and is often seen by 
contemporary health care providers for the first time in cases of emergency.  ANC that 
incorporates health education and proper blood pressure screening will ensure that onset 
and progression of disease are either diverted or properly managed.  Management at the 
onset of uncontrolled hypertension using anti-hypertensive medications such as 
nifedipine, hydralazine, and methyldopa will regulate blood pressure to safe levels, with 
the intent of preventing disease progression to severe pre-eclampsia or eclampsia.   
Therapy for preventing or halting convulsive seizures using magnesium sulfate 
(MgSO4) is standard of care in the U.S. and is recognized by the WHO as the preferred 
method of treatment.  Other common therapies in under-resourced settings are diazepam 
(valium), phenytoin (anticonvulsant), and lytic cocktail (mixture of chlorpromazine, 
promethazine and pethidine), yet resolution of the disease lies in delivery of the fetus and 
placenta regardless of gestational age.   
Diazepam is currently most often used to treat eclampsia in all regions of Nigeria. 
It began use as an anti-convulsant treatment for eclampsia in the 1960s (Lean 1968).  A 
team of researchers led by Lelia Duley has done extensive research over the past twenty 
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years on MgSO4 compared to other therapeutics for eclampsia.  They have proven it to 
be the most effective and safest therapy for treating eclampsia.  In regards to the 
historical and continued popularity and use of diazepam they explain, “ Diazepam is a 
core medicine in the World Health Organization‟s ‟Essential Drugs List‟, which is a list 
of minimum medical needs for a basic healthcare system, and has been one of the most 
frequently prescribed medications in the world for the past 40 years. This wide 
availability probably contributed to its initial acceptance as a treatment for women with 
eclampsia.  Treatment with diazepam usually includes a loading dose of 40mg by 
intravenous injection, followed by an infusion of 20mg diluted in 500 ml. This infusion is 
titrated against the level of sedation, with the aim of keeping the woman drowsy but 
rousable.” (Duley, Henderson-Smart, Walker, & Chous, 2010 p. 4).   
They also explain the two common dosing regimens of MgSO4, named after Drs. 
Pritchard and Zuspan.  The Prichard regimen is characterized as an initial loading dose of 
14 grams: intravenous loading dose of 4 grams and 10 grams by intramuscular injection. 
This is followed for 24 hours by 5 grams intramuscular injection every 4 hours 
(Pritchard, 1955).  The Zuspan regimen is an initial intravenous loading dose of 4 grams, 
and followed by maintenance intravenous infusions of 1 gram per hour for 24 hours 
(Zuspan, 1978).  There is some concern with toxicity of MgSO4 and so monitoring is 
needed when administering this therapy.  Signs of toxicity include: patellar reflex loss, 
respiratory paralysis, renal failure and thus monitoring for tendon reflexivity and 
respiration is sufficient as indications to reduce dosing (Duley, Henderson-Smart, 
Walker, & Chous, 2010).  MgSO4 is found to be safe, effective, and inexpensive as 
reported from within the Nigerian research community at $.35/dose (Ladipo, 2009).  
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  Ideally, delivery is delayed through expectant care, i.e. treating the symptoms of 
the disease to allow fetal lung maturity and viability when possible. However in low-
resource settings a host of factors often prohibit emergency cesarean delivery, provision 
of effective therapeutics and conservative expectant management, and adequate 
monitoring complemented by intensive nursing care (Hunyinbo, Fawole, Sotiloye & 
Otolorin, 2008; Lombaard, Pattinson, Backer, & Macdonald, 2005).   
The relevance of MgSO4 to maternal morbidity and mortality will be discussed 
throughout this paper, with attention given to the current poor status of women‟s health in 
Nigeria due to this disease.  The trends in therapeutic management of pre-eclampsia and 
eclampsia in Nigeria are discussed using a review of the available research data specific 
to management practices in this West African country.    
 
Search strategy including criteria for selection of articles 
Articles were chosen that:  (1) reported therapeutics related to pre-eclampsia and 
eclampsia; (2) were published in peer-reviewed journals in English between 2000 and 
2011, although the research may have been conducted prior to 2000; (3) the research was 
conducted in African institutions, (4) and reported on the general African population and 
specifically Nigerian populations. Nigeria was selected because the initial search revealed 
more published articles for this country in the last ten years than other sub-Saharan 
African countries.  Also, the current status of disease management in Nigeria is 
significant because it has one of the highest rates of maternal mortality due to pre-
eclampsia and eclampsia worldwide, approximately 30% (Tukur, 2009; Ikechebelu & 
Okoli, 2002).   
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Literature Search and Retrieval Process 
PubMed, Web of Science, African Index Medicus and the WHO database were 
resources used.  MeSH search terms included: pre-eclampsia, eclampsia, therapy, 
therapeutics, magnesium sulfate, diazepam, phenytoin, lytic cocktail, randomized control 
trial, Africa, and Nigeria.  These terms were joined as needed to produce desired results. 
Then a hand search was done of the reference lists of research articles and reviews to 
cross check the articles collected.  The article review spanned 2000 to 2011.  The articles 
where then categorized by geographic location within sub-Saharan Africa and therapy.  
The inclusion criteria for articles in this review are as follows: a description of a specific 
management strategy was provided to a Nigerian geographical sub-population, and a 
review of outcomes based on a management strategy.     
To rate quality of individual articles, the author independently reviewed each 
article.  The method of review was based upon a 12 point checklist (Appendix A) for 
critical reading of medical literature. A limitation of this review is that there were not 
randomized controlled trials (RCTs) available within the timeframe of the review and the 
geographical region chosen.  It has been documented that there is a paucity of clinical 
research in developing countries that uses the gold standard RCT format and is rigorous 
and consistent (Daniels, Lewin, & Practice Policy Group, 2008; Lavis, Davies et al., 
2005).  Identified for this review were one prospective case control study and seven 
retrospective chart reviews as relevant to specific management criteria. With plans for a 
meta-analysis the author adapted the approach described by West et al. (2002).  That 
system incorporates:  (1) quality of the individual studies as assessed by examination of a 
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checklist of specific elements of study design and conduct; (2) quantity of relevant 
studies identified; and (3) consistency of findings.   
Subsequently, papers regarding management of pre-eclampsia and eclampsia 
were reviewed for 1. presence of disease,  2. administration of therapeutic for disease, 3. 
effect of therapeutic treatment on maternal health, and 4. effect of therapeutic treatment 
on neonatal health. Again, since no RCTs were found during the search that would 
compare treatment and therapeutic management options within this population, this 
literature review is a reflection of the lack of rigorous research and information 
dissemination underway in Nigeria to date.  It does, however, reflect outcomes based on 
current practice as reported within secondary and tertiary health care facilities in the 
country. 
 
Critical review of the selected literature 
 Eight articles were chosen for review and discussion.  All of the selected studies 
were conducted in a Nigerian research setting.  Seven are retrospective chart reviews and 
one is a prospective case-control study.  All of the articles combined cover a time span 
from 1994-2007. Appendix B describes the location and type of study, therapeutics and 
observations, and outcomes.  This author will discuss the articles chosen for review in 
chronological order, from oldest to most recently published.   
The first is the only prospective case-control study identified, and the only study 
focusing on antepartum, second trimester, and timing of onset of disease: Conservative 
management of early-onset pre-eclampsia and fetomaternal outcome in Nigerians, Onah, 
H.E. and Iloabachie, G.C., 2002. The purpose of the study was to compare maternal-fetal 
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outcomes of patients with disease onset before 30 weeks gestation to the same outcomes 
for patients with onset after 30 weeks gestation in the presence of conservative 
management (monitoring and medication).  The authors directly hypothesize that the 
conservative versus aggressive management (surgery or labor induction) of disease in the 
second trimester would result in more favorable maternal-fetal outcomes.  
Using the criteria set forth by Schulz and Grimes (2006) for assessing scientific 
rigor in case-control studies it was noted that all consecutive cases presenting at the 
University of Nigeria Teaching Hospital in Enugu were included.  “Hypertension was 
defined as persistent sitting blood pressure of 140/90mmHg or greater using Korotkoff 
phase V [sounds]” (p. 357).  Pure preeclampsia was defined as hypertension combined 
with proteinuria in a previously normotensive patient, and super-imposed pre-eclampsia 
occurred in a patient with prior history of hypertension coupled with proteinuria. 
Confounding between the two groups was not addressed.  
749 pre-eclamptics were included in the study group from 1995-2000.  Of those, 
23% (175) were enrolled before 30 weeks gestation, becoming the case group while the 
remaining 77% (574) served as the control group with onset of disease after 30 weeks 
gestation.  Of the cases, 91 had pure pre-eclampsia and 84 had superimposed pre-
eclampsia.  21 (12%) cases developed eclampsia of which 7 died, and 98 (17%) controls 
developed eclampsia of which 7 died.  Conservative management for all participants was 
listed as: bed rest, anti-hypertensive medication (methyldopa or hydrallazine) as needed, 
and diazepam for seizures.  The regimen for antepartum hypertensive medication was 
oral alpha-methyldopa and hydrallazine infusion 40mg/L of 5% dextrose in water with 
onset of pre-eclampsia.  Blood pressure goal in the absence of labor was 140/90 
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to150/100mmHg.  In the antepartum case group delivery was delayed for as long was 
maternal-fetal risk did not warrant intervention.  For the control group the gestational age 
at onset likely fell past the 34
th
 week gestation and delivery was not delayed.  The mean 
gestational age for onset in the case group was 24.2 ±3.5 (SD) weeks with delivery at 
average 33.0±5.0 weeks; and the mean gestational age at onset for the control group as 
35.9±3.0 weeks and delivery at 36.9±3.0 weeks.   
In the cases and controls, other causes of death were renal failure, HELLP 
syndrome, anesthesia accidents, placental abruption and cerebro-vascular event.  MMR 
for cases and controls combined was 5600/100,000 (42 deaths).  The control group saw 
twice the maternal mortality than the early on-set, case group.  Nearly half of the women 
enrolled in each arm of the study delivered via cesarean section most often due to 
imminent eclampsia and a failure of ripening of the cervix.  Neonatal results are as 
follows: mortality rate for combined study arms was 272/1000.   Due to low birth weight 
and preterm deliveries the case study group diagnosed with pre-eclampsia prior to 30 
weeks experienced higher incidence of mortality (48.3% compared to 20.8% of controls).   
This article concludes that conservative management at the early onset of 
preeclampsia is related to better neonatal outcomes, but less favorable maternal 
outcomes.  The incidence in the early onset group was almost twice that of the late onset 
group.  The authors site an increase in MMR in Nigeria in the past 20 years.  They say 
MMR rose in their health care facility from 270/100,000 to 1406/100,000 between 1976 
and 2000.  This is attributable, according to this article, to the rise in prevalence of pre-
eclampsia and eclampsia coupled with a lack of ANC and the continued inadequate 
supply of MgSO4 to manage these patients.    They also found longer decision-
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intervention intervals contributed to the higher mortality rate.  Decision time increased an 
average of 1.5 hours to 6 hours because of hospital policy change and worker 
dissatisfaction (Onah, 2002). 
Second is Review of eclampsia at the Nnamdi Azikiwe University Teaching 
Hospital, Nnewi (January 1996-December 2000), Ikechebelu, J.I. and Okoli, C.C. 2002. 
MMR for this hospital during these years was listed as 330/100,000.  This five-year 
retrospective review of 43 cases of eclampsia compared age, parity, booking status, the 
gestational age and blood pressure at onset of seizures, treatment regimen, and mode of 
delivery.  An eclampsia diagnosis was determined by tonic-clonic convulsions.   Briefly, 
the investigators found at this hospital that 32.6% were young (21-25 year-old), first time 
mothers (65%), who had received no ANC (83.7%) were more likely to have eclampsia 
in the antepartum period (55.8%) and delivery via cesarean (85.7%).  Diazepam was the 
anticonvulsant used in all cases. 9.3% (4) of the cases resulted in maternal death.  
Incidence for eclampsia in this hospital accounted for 0.75% of deliveries.  Neonatal 
mortality was 16.3% of charts reviewed (7 deaths).  Two of those babies died at the 
hospital (low birth weight and asphyxia) and five died before the woman reached the 
hospital for care.  Within the discussion this study further compares eclampsia mortality 
rates across regions of Nigeria.  They compared their institution‟s 0.75% (43/5750) 
eclampsia incidence as similar to Lagos and Ibadan in the southern coastal region of 
Nigeria; and higher than Enugu (0.29%) and Benin City (0.46%).  They also compared 
age, parity, booking status, and gestational age at onset with other areas of Nigeria. All 
comparisons were similar except for in Ile-Ife where the majority of eclamptic 
convulsions occurred intrapartum rather than antepartum.   
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The authors report their study period as an unstable time for the public health care 
system in the Nnewi region in which residents were opting for private specialist care 
resulting in fewer deliveries and referrals and therefore lowering the overall incidence for 
this study.  This study acknowledges that MgSO4 is not available in this hospital and that 
it is a superior option to diazepam.  They noted a lack of prostaglandin pessaries for aid 
in cervical ripening as a cause of high mortality, morbidity and cesarean outcomes.  
These authors recommend patient education, provision of management protocols for use 
and routine review, and infrastructure improvement to increase access to care for women 
in the region to prevent incidence of morbidity and mortality from eclampsia (Ikechebelu 
& Okoli, 2002). 
 Third is, Pregnancy outcomes of women with eclampsia in Gombe, Nigeria, 
Melah, G.S. Massa, A.A., and El-Nafaty, A.U., 2005.  Gombe is in the rural northeastern 
part of Nigeria where eclampsia is the number one cause of maternal death.  Modern 
ANC services are not widely available or accepted in the area.  Researchers hypothesize 
that eclampsia is preventable in women who receive ANC, and thus reviewed medical 
charts of women with eclampsia from January 1997 to December 2000.  This study 
aimed to assess age, parity, booking status, and pregnancy outcomes of women with the 
diagnosis.  67.8% of those diagnosed were teen-aged, and 79.8% were first time mothers. 
The eclampsia incidence at this hospital was 3.7% (438/11,986).  MMR was 
2058/100,000 (47 of 228 maternal deaths due to eclampsia). Eight women died 
undelivered. Vaginal deliveries were 51.0% due to presentation while in labor.  Neonatal 
mortality due to eclampsia was 2023/100,000 (157 infants), with the following outcomes: 
preterm, intrauterine fetal demise (IUFD) and low birth-weight.  Disease management 
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was not specifically noted other than stating that MgSO4 is not available in the labor and 
delivery unit, and that if it were available the incidence of maternal mortality would be 
significantly reduced.   The study indicates that warning signs leading up to the first 
seizure were present in 91% of cases, which implies the probability for a pre-eclampsia 
diagnosis and course of treatment had these patients received ANC.  Maternal fatality rate 
was 10.7% (Melah, Massa, & El-Nafaty, 2005).   
Fourth, Eclampsia: ten-years of experience in a rural tertiary hospital in the 
Niger delta, Nigeria, Igberase, G.O., and Ebeigbe, P. N., 2006.  This retrospective chart 
review covered cases from January1994 - December 2003.  The setting was a rural 
tertiary medical center serving the (south central) Nigerian Delta catchment area for more 
than half a century.  The authors set out to assess a pattern of clinical presentation and 
maternal-fetal outcomes in a rural hospital setting, they referred to this as „highlighting 
the peculiarities of the experience of eclampsia in rural areas” in order to improve care (p. 
414).  Specific to this hospital is that it provides specialist in-patient and out-patient 
OB/GYN, pediatrics, and internal medicine services (p415).  Upon intake of an eclamptic 
patient, this facility utilizes pulse oximetry, oxygen facemasks, and claims to have used 
MgSO4 for treating eclamptic seizures for the past fifteen years.  The protocol for 
diagnosing eclampsia is clearly stated as using the Pritchard method (tendon reflex, urine 
output, respiratory rate, and hydalazine and nifedipine to control hypertension.  
Eclampsia occurred in 2.3% (123 cases) of the 5,242 deliveries during the ten-year 
period, there were 19 maternal deaths – acute renal failure was listed as the primary cause 
of death.  Neonatal mortality was 195/1,000 live births (24 deaths).  This study reports 
their eclampsia rates to be more than 40 times the incidence in developed countries (p. 
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416).   The women who presented in this study were mostly seen by a traditional birth 
attendant and brought to the hospital for eclamptic seizure. Eighty-two delivered via 
cesarean section, 31 vaginal delivery and 10 assisted delivery  
Patterns are described as being in agreement or disagreement with other study 
findings in other regions of Nigeria is as follows: authors claim a higher incidence of 
disease for this review compared to urban centers in Nigeria.  This is attributable to 
access-to-care issues and more common use of traditional birth attendants (46% of 
women use a traditional birth attendant in this region).  80% of women were unbooked 
for ANC and it took over 12 hours from first seizure for 48% of the women to get to the 
hospital, which accounts for 66% delivering via cesarean section.  There appear to have 
been prior symptoms of disease in 75% of women in this study. The lack of ANC which 
would include provider supervision and patient education contributed to this lack of early 
intervention.  As consistent with other studies young, unbooked, primigravida women 
who seized prior to laboring (antepartum) were the most commonly affected group in this 
study.  They reported the MgSO4 had not reduced the cesarean rate since it is the same as 
other Nigerian hospitals using diazepam, and MgSO4 use did not improved neonatal 
outcomes.  Maternal case fatality rate was 15.4% consistent with others reported in 
Nigeria between 9 and 17 %.  Maternal death most often resulted from renal and 
cardiopulmonary failure.  Conversely, neonatal death resulted from preterm, asphyxia 
and sepsis.  The use of MgSO4 cannot be identified as protective in this study due to late 
presentation for care.  Authors‟ recommend traditional birth attendant integration into 
formalized health services delivery (Igberase, & Ebeigbe, 2006).  
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Fifth, is Critical care management of eclamptics: challenges in an African setting, 
Okafor, U.V. and Efetie, R.E., 2008.  This retrospective study focuses on the 
management and outcomes for eclampsia patients admitted to an intensive care unit 
(ICU) unit in a referral hospital in Abuja, the capital city of Nigeria.  Medical chart 
abstraction on 38 (32 unbooked) ICU records was done between November 2001 and 
April 2005 for eclamptic patients.  Patient demographics, booking status, parity and 
gestational age at delivery and at onset of seizures were documented.  All patients were 
admitted to the ICU unit postpartum, however 20 had onset antepartum, six intrapartum 
and 12 postpartum.  Average age of patients was 28 years (range 17-40).  Twenty-three 
patients were first time mothers.  Twenty-nine delivered via cesarean section and nine 
delivered vaginally.  Diazepam was used to control seizures – except for one patient who 
received MgSO4 due to its recent availability.  Hydralazine was used to control high 
blood pressure.   
This facility had airway management via intubation equipment. The following 
monitoring measures are documented: electrocardiograph (ECG), pulse oximeter, blood-
pressure, temperature, urine output and capnography, which measure carbon dioxide 
(CO2) production.  Criteria for admission were seizure frequency, arterial oxygen 
saturation, and Glasgow coma scale (GCS).  Atracurium or pancuronium was used for 
long term neuromuscular blockage as available and dependent upon the patient‟s blood 
pressure.  Outcomes were as follows: there were 11 maternal deaths (case fatality rate of 
29%).  45% (17) patients were put on ventilation due to the respiratory depressive action 
of the diazepam sedation which lowered the GCS scores.   
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Authors estimate MgSO4 in lieu of diazepam would decrease the instances and 
need for mechanical ventilation assistance in eclamptic patients, and prevent pre-
eclampsia from progressing to eclampsia.  Authors attribute the death rate to use of 
diazepam, late management of disease, and lack of ANC.  Also blamed is a lack of direct 
invasive arterial and venous blood pressure monitoring equipment in this ICU.  Poverty 
and a lack of ICUs and anesthetists are noted as the cause of maternal deaths in this 
country (Okafor, & Efetie, 2008).  
The sixth article is Anesthetic management of patients with pre-
eclampsia/eclampsia and perinatal outcome, Okafor, U.V., Efetie, E.R., Igwe, W., and 
Okenzie, O. 2009.  This study was done in a teaching hospital in Enugu.  It is another 
retrospective chart review (1998-2006).  The purpose of this study was to look at risk 
factors for neonatal mortality associated with anesthesia for cesarean delivery in patients 
with a preeclampsia or eclampsia diagnosis.  Charts were reviewed for patients diagnosed 
with pre-eclampsia and eclampsia, for mode of delivery and outcomes specific for 
cesarean section.  Pre-eclampsia was defined as pregnancy induced hypertension with 
proteinuria ≥300mg/24hour after 20 weeks gestation. Perinatal mortality in this article 
refers fetal demise and neonatal death within seven days postpartum.  Outcomes were 
stillbirth, neonatal death, maternal mortality and anesthesia type.  285 women had 
preeclampsia/eclampsia diagnoses. 196 of the pre-eclamptic and eclamptic women 
delivered via cesarean.  This article specifically states that a protocol for prophylactic 
MgSO4 is present, but because of cost (to the patient) and availability, it is not frequently 
used.   However, the authors‟ claim that a recent donation from an unnamed source of 
MgSO4 has ramped up use.  Of the sedated patients there were 157 under general 
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anesthesia, 24 under spinal anesthesia, and 5 under epidural anesthesia. This study did not 
report on maternal morbidity, but suggested a „drastic‟ improvement at this center 
attributed to improved anesthesia care.  There were 19 still births and 19 perinatal deaths 
(PMR 180/100,000), 30 occurring under general anesthesia.  Authors attribute the PMR 
to lack of ANC and underuse of MgSO4.  They address the side effects of diazepam on 
the neonate referring to it as „neonatal withdrawal‟.  These withdrawal symptoms 
include: hypertonia, hyperreflexia, restlessness, irritability, abnormal sleep patterns, 
inconsolable crying, tremors or jerking of arms and legs, bradycardia, cyanosis, sucking 
difficulties, apnea, aspiration of milk, diarrhea, vomiting and growth restriction. These 
symptoms are known to last up to 3 weeks postpartum – and sometimes months.  This 
study suggests regional anesthesia, which is spinal or epidural, to produce improved 
neonatal outcomes when a cesarean is needed to address pre-eclampsia and eclampsia 
(Okafor, Efetie, Igwe, & Okenzie, 2009). 
The seventh article in this literature review is, A 5-year review of maternal 
mortality associated with eclampsia in a tertiary institution in northern Nigeria, Kullima 
A.A., Kawuwa, M.B., Audu, B.M., Usman, H., Geidam, A.D., 2009.  This review spans 
from 2003-2007 for eclampsia related deaths in Federal Medical Centre Nguru; Nguru 
State borders Niger.  The purpose of this study was to see if the incidence of maternal 
mortality from eclampsia is associated with the social demographics of patients. 
Outcomes were for mortality, time of eclampsia, mode and place of delivery, socio-
demographics, and neonatal outcome.  Fifty-two records of women who died from 
eclampsia were analyzed representing 46.4% of maternal deaths over the five year period.  
This study listed the eclampsia related maternal mortality ratio as 1322/100,000. 
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Maternal case fatality was 22.3%, which was higher than other parts of Nigeria: Benin 
(10.7%), Gombe (11.6%), Ukpoma (15.4%), and Jos (16.9%).  About half of the 52 
maternal deaths occurred in antepartum cases; intrapartum was 34.6% and postpartum 
was 15.4%.  Of those who died there were nine cesarean sections, 15 assisted deliveries, 
and 17 vaginal deliveries. Eleven women died undelivered.  Of the 52 maternal deaths 51 
were illiterate and 49 did not receive ANC.  Excluding the 11 mothers who died 
undelivered, of the 41 remaining mothers 23 babies lived and 18 were still born.   
There were a total of 224 managed cases of eclampsia reported, 80.5% delivered 
at the hospital.  Of those 224 women 194 were illiterate and 204 did not receive ANC.  
Neonatal prognosis was better at antepartum diagnosis because cesarean section was 
possible at this tertiary facility.  However, women with an eclampsia diagnosis in the 
antepartum stage where more likely to succumb to the disease.  Diazepam was the 
anticonvulsant prescribed in all cases.  Attributable to the high MMR in this rural 
northern region of Nigeria are a lack of access to emergency obstetrical care and a 
paucity of skilled birth attendants (Kullima, Kawuwa, Audu, Usman, & Geidam, 2009). 
Last in the review is, Management of eclampsia at AKTH: before and after 
magnesium sulphate, Tukur, J., and Muhammad, Z., 2010.  This article reviews patient 
records for women who delivered at Aminu Kano Teaching Hospital (AKTH) in Kano, 
Nigeria from January 2002- December 2004 and December 2005-December 2007 
constituting the „before‟ and „after‟ portions of this review.  Kano is located in north 
central Nigeria.  The goal was to compare the influence of MgSO4 and diazepam on 
maternal outcomes.  131 maternal medical charts were reviewed out of 163 cases of 
eclampsia during the time period of interest.  Outcomes of interest were MMR, PMR, 
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Apgar scores at 1 and 5 minutes, toxic effects of MgSO4, time of presentation and 
booking status.  Thirty-eight women with an eclampsia diagnosis received diazepam, 15 
(39%) of which died.  93 eclamptics received MgSO4 as treatment after it became 
available, 14 (15%) of which died.  This was statistically significant for use of MgSO4 to 
reduce MMR. Total PMR was 312/1000 live births (41). The difference for PMR 
between the two therapies was not statistically significant; PMR for diazepam: 368/1000 
and for MgSO4: 297/1000 live births.  For comparing Agar scores between the two 
groups the authors reported Apgar scores of six or less at one minute in 80.2% of 
diazepam cases and 94.7% of MgSO4 cases, and at five minutes the 6 or less in 46.2% of 
diazepam cases and 57.9% of MgSO4 cases.   Infants in the diazepam group were likely 
affected by sedative properties of the drug and thus demonstrated more negative scores. 
Toxicity of MgSO4 was not described in detail; however, toxicity was reported as seven 
with renal complications and one with respiratory complications, and the outcomes were 
not given.  Delay of care of more than 6 hours from onset of the first seizure played a 
significant role in maternal deaths.  Out of a total of 29 deaths 25 delayed care and 4 did 
not delay care.  The authors conclude this study is in agreement with other research in 
determining the MgSO4 improves maternal outcomes for eclampsia (Tukur, Muhammad, 
2010). 
 
Interpretation of findings 
This review is meaningful for two reasons. First, within this review of Nigerian 
generated research articles six cite the lack of MgSO4 as a cause of elevated MMR; and 
one article demonstrates by comparison that MgSO4 produces lower MMR than 
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diazepam.  There is long standing evidence from the multi-country RCT, the Magpie 
trial, released in 1995, and subsequent Cochrane Reviews establishing MgSO4 as the 
most effective, inexpensive treatment for ceasing eclamptic seizures and protection 
against the progression of pre-eclampsia to eclampsia (Woelk et al., 2009; The 
Eclampsia Trial Collaborative, 1995; Altman et al., 2002; Duley, Gulmezoglu, 
Henderson-Smart,& Chou, 2010; Duley & Henderson-Smart, 2003a; Duley & 
Henderson-Smart, 2003b; Duley, 2005).  Second, is that it reflects a portion of 
continuous reports and reviews over the past 15 years that have focused on the 
unavailability and under use of MgSO4 therapy in Nigeria.  There appears to be no 
significant changes in practice happening today as reported by Langer (2008), “Although 
magnesium sulfate has been the standard treatment in developed countries for 20 years, 
less effective and higher-risk drugs (eg, diazepam and phenytoin) are still widely used in 
most developing countries.” (Adewole, 2000; Langer, Villar, Tell, Kim, & Kennedy, 
2008; Tukur, 2009). 
Five of the studies gave diazepam as the anticonvulsant used to treat eclamptic 
patients.  One stated the absence of MgSO4 as a lifesaving therapy, but did not list the 
anticonvulsant used.  And one review completed in 2002 in southern central Nigeria 
stated, “Diazepam has remained the most popular regimen in the management of 
eclamptic fits in our hospital. It also appears to enjoy wide acceptability in other centres 
in Nigeria. Other regimes such as lytic cocktail, phenytoin and magnesium sulphate are 
not popular” (Ikechebelu & Okoli, 2002, p. 289).  This is problematic because of the 
proven superiority of MgSO4 as management of pre-eclampsia and eclampsia. Duley, 
Henderson-Smart, Walker, & Chou (2010) reviewed seven RCTs, involving 1396 
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Figure 1. Place of births in Nigeria 
NDHS, 2008 
women.  They found that for women with eclampsia, “using MgSO4 rather than 
diazepam reduces the [risk ratio] RR of maternal death by 41% (95% CI 8% to 62%) and 
of recurrence of seizures by 57% (95% CI 45% to 67%)” (p.12).  Their review also 
reported better neonatal outcomes with better Apgar scores for babies using MgSO4 than 
with diazepam; however there were insignificant changes to admissions to a NICU, but 
the MgSO4 group had a <7day length of stay, fewer than the diazepam group.  
Effectiveness of MgSO4 in developing, sub-Saharan African countries was shown 
with the inclusion of Mozambique, South Africa and Zimbabwe in the Magpie Trial. 
MgSO4 was proven to reduce risk of eclampsia by more than half (58%) and save 
maternal lives with relatively low incidence of mild side effects (headache, nausea and 
vomiting), which were reported in 25% of the women who participated (Duley, 
Henderson-Smart, Walker, & Chou, 2010; Altman et al., 2002).  The articles chosen for 
review suggest that researchers in academic settings and providers in public hospitals in 
Nigeria are well aware of the superior therapeutic effects of MgSO4.  There is an ongoing 
need for consistent provision of the first line, effective therapeutic MgSO4 for prevention 
of disease.   
Five of the eight articles stress the 
importance of ANC to promote identification and 
proper referral and reduce the number of obstetric 
emergencies related to pre-eclampsia and 
eclampsia which lead to maternal-fetal morbidity 
and mortality.  In Nigeria, three in five births (62 
%) occur at home (see Figure 1).  MEASURE 
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Demographic Health Survey defines ANC as obstetric care “provided by a skilled health 
worker [which] enables:  1) early detection of complications and prompt treatment (e.g., 
detection and treatment of sexually transmitted infections);  2) prevention of diseases 
through immunization and micronutrient supplementation;  3) birth preparedness and 
complication readiness; and;  4) health promotion and disease prevention through health 
messages and counseling of pregnant women” (NPC & ICF Macro, 2009 p. 125).   
Also, significant to this review is the understanding that no single improvement 
will change the high incidence of maternal-fetal mortality in Nigeria related to pre-
eclampsia and eclampsia. In the past five years MMR has dropped by nearly 150,000 
cases worldwide, but has only decreased by 92/100,000 deaths in Nigeria, according to a 
recent review comparing MMR in 181 countries (Hogan et al., 2010). 
 
Policy implications/recommendations and significance for MCH 
 In order to make a significant improvement in Nigeria in maternal and neonatal 
morbidity and mortality related to the management of pre-eclampsia and eclampsia an 
assessment of the health care system and pharmaceutical market in Nigeria is needed.  
Also, the involvement of stakeholders with decision-making power, such as government 
health officials; those with funding, such as NGOs and bilateral and multilateral agencies; 
and those with clinical responsibilities, such as clinician-researchers, medical officers and 
traditional birth attendants will initiate change in current practice.  Fostering alliances 
between providers and policy makers within the Nigerian states requires careful 
consideration and cultural competence, since there are 37 states divided into 774 local 
governments (Ladipo, 2009).  Also, facilitating the identification of barriers between 
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Figure 2. AMDD building blocks framework for emergency 
obstetric care. 
practice and evidence-based 
medicine with the 
appropriate authority and 
stake-holders requires 
diplomacy, but is an 
effective catalyst for change.  
The pyramid (Figure 2) 
demonstrates that 
assessment of Nigeria‟s 
health care infrastructure, 
health professionals and continued monitoring is essential to make way for use of life 
saving interventions like MgSO4 that are not the current standard of practice.  This 
framework was identified by the Adverting Maternal Death and Disability Program 
(AMDD) as essential components to improving health services delivery(AMDD, 2010).  
Seven strategic steps are identified as precursors to development of community capacity 
to generate this change. 
The first step of assessment for the implementation of new practices and 
policies is building alliances among stakeholders.  Stakeholders need to identify the 
baseline of evidence-based practice culture in the health care sector in order to begin the 
process of changing it (Woelk, 2009).  Second, is to determine the extent to which the 
political environment is receptive to the creation and enforcement of public health 
policy. A few examples of recent policy in Nigeria include: Reproductive Health 
Commodity Security Strategic Plan (RHCS plan2003); the Road Map for Accelerating 
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Basic EmOC include: 
 Treatment for sepsis 
 Treatment for eclampsia 
 Treatment for prolonged or obstructed labor 
 Post-abortion care (PAC) 
 Treatment for incomplete miscarriage 
 Removal of the placenta 
 Assisted delivery using forcepsor suction 
 
Comprehensive EmOC services include the services 
listed above, and also: 
 Surgery (specifically, Caesarean section) 
 Anesthesia 
 Safe blood transfusion observing universal HIV 
precautions 
Figure 3. Emergency Obstetric Care 
the Attainment of the MDGs Related to Maternal and Newborn Health in Nigeria, 2005; 
and Integrated Maternal, Newborn and Child Health Strategy, 2007 as reported by Ladipo 
in a 2009 conference presentation in Nigeria.  Detailed information regarding these 
policies is not readily available. It may be that these recent policies address the use of 
MgSO4, which would reflect progressive movement.   
As a part of relationship cultivation, inquiry and discussion of these policies is 
required. In the interest of increased provision and use of MgSO4, policies related to 
health professional education standards, task shifting and pharmaceutical attainment and 
allocation are sought.  In this vein, to increase MgSO4 use stakeholders must appeal to 
the Nigerian Federal Ministry of Health to re-evaluate the status of drugs on the Nigerian 
formulary list.  They must lobby for MgSO4 availability in tertiary health care centers 
and village dispensaries. 
Third is assessment of health care facilities within each state. The Adverting 
Maternal Death and Disability Program (AMDD) affiliated with Columbia University has 
published an emergency 
obstetric care (EmOC) 
needs assessment field 
guide and data 
collection modules in 
response to the need to 
improve health systems 
in developing countries.  
These modules cover 
29 
PRE-ECLAMPSIA AND ECLAMPLSIA MANAGEMENT IN NIGERIA 
Identification of Facility and Infrastructure; Human Resources; Essential Drugs, 
Equipment, and Supplies; EmOC Signal Functions and Other Essential Services; 
Provider Knowledge and; Cesarean Delivery Review; and a Maternal Death Review 
(AMDD, 2010).  These validated data collection instruments will take a current snapshot 
of facilities to further demonstrate gaps in care for women with pre-eclampsia and 
eclampsia and other obstetric complications in each Nigerian state (WHO, 2009).  This 
information can be compared and supplemented by a similar 2003 report of health 
facilities in 12 Nigerian states where 4.2% of health care facilities met the Basic Essential 
Obstetric Care (BEOC) and 1.2% met Comprehensive Essential Obstetric Care(CEOC) 
criteria (see Figure 3) (Fatusi & Iiadunola, 2003; Raise Initiative, 2007).  
Fourth is understanding the complex motivations of health care providers 
and the factors that may influence use or demand for MgSO4, which seem to stem from 
historical drug access, experience-based practice, cost, and fear of side effects (Sevene et 
al., 2005; Laing, 2003).  A paper recently presented at the 2009 Nigerian National Health 
Conference by M.S.I Ohuabunwa addresses the challenges of essential drug availability 
in the country.  Dr. Ohuabunwa sites corruption, poverty, budgetary restrictions, and a 
poorly supported pharmaceutical industry as the reasons for lack of appropriate 
therapeutics such as MgSO4.  He explains that once drugs reach clinics and pharmacies 
they are pocketed or re-sold; also, that competition with India and China make it difficult 
for national pharmaceutical companies to thrive. This is true especially in an inadequate 
industrial environment as is the case in Nigeria.  Ohuabunwa faults recent World Trade 
Organization (WTO) policy for making Nigeria an open door for pharma trade and the 
influx of fake drugs (Ohuabunwa, 2009).  Moreover, a study of perinatal care providers 
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lack of use of evidence-based reproductive health interventions in neighboring Cameroon 
suggests the provider related barriers are: a lack of continued medical education (CME), 
inadequate formal training, insufficient access to learning resources e.g., journals, 
newsletters, and data, and a culture that does not promote self-learning(Tita, 2005).  
Another barrier specific to Nigeria is widespread use of other anticonvulsant therapy 
(diazepam) that can be used for other health indications e.g. sedation, pain relief, anxiety, 
insomnia, seizures, and muscle spasms (Duley , Henderson-Smart, Walker, Chou, 2010).  
Fifth, educating the public and health sectors through health promotion efforts 
and continuing medical education (CME).  Special attention must be paid to traditional 
birth attendants on the importance of antenatal care and basic emergency obstetric care 
practices (See Figure 3).  Already the WHO has advocated that in resource-limited 
settings only tests that are proven to impact maternal-fetal outcomes be offered at the 
antenatal care visit. These tests have been determined as blood pressure, urine tests for 
bacteria and protein, and blood tests for syphilis and anemia (WHO, 2001; Osungbade, 
Oginni & Olumide, 2008).  Consideration towards task-shifting and training traditional 
birth attendants in these basic skills would likely increase antenatal care throughout the 
country, but particularly in the rural areas.  
Improved access and patient acceptance of antenatal care is needed in the case of 
pre-eclampsia and eclampsia for early detection, birth preparedness and complication 
readiness as stated in the DHS Nigeria Report for 2008.  Again, integration of traditional 
birth attendants into the antenatal care and referral system for these same lines of defense 
is needed.  Particular emphasis should be put on the higher risk young primigravida 
women have of to developing this diease.  Also, because antenatal care and diagnostic 
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testing cannot necessarily predict the onset of pre-eclampsia or eclampsia women have to 
have awareness about where to go for basic and comprehensive emergency obstetric 
management. 
Educating providers to best practices is as essential as providing them with the 
therapies that are known to produce the better outcomes.  Sixth is the assurance of drug 
availability.  MgSO4 has been on the WHO essential medicines list (EML) since 1996, 
one year after the dissemination of the Magpie trial evidence.  It is categorized under 
anticonvulsants/antiepileptics with the caveat: “For use in eclampsia and severe 
pre‐eclampsia and not for other convulsant disorders” (WHO, 2010).  It is also listed in 
the latest 2003 version of the EML for Nigeria published by the Federal Ministry of 
Health and WHO (Sevene et al. 2005).  In the Nigerian EML the therapeutic appears 
under the „List of Essential Drugs” heading, yet is not present in “The Primary Health 
Care List” under the anticonvulsant category (diazepam injection, paraldehyde injection, 
and phenobarbitone tablet are listed). This primary health care list is meant for drugs 
which are considered essential for specialist and tertiary health care facilities.  However, 
it is listed for use as a purgative drug or laxative under “Products to be Stocked and Sold 
by Patent Medicine Dealers/vendors.” The patent medicine vendors are much like corner 
drugstores in the U.S. and not likely to sell prescription medications.  Notably, there is no 
anticonvulsant medication listed for Level B – Village Dispensaries (Federal MOH Abuja 
Nigeria, 2003).  At thirty five cents per dose (ampoule (40ml of 10% MgSO4) there is an 
unnecessary breakdown in availability of this life-saving therapy as is evident in the 
literature reviewed above.  Simon, Gray & Duley (2006) conducted a economic 
evaluation of use of MgSO4 and found that in low gross national income countries like 
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Nigeria administering MgSO4 adds $11 to hospital costs.  They also report an 
institutional savings of $456 for one missed case of eclampsia.  This included cost 
savings for all aspects of antenatal and post natal care for both mother and baby: 
administrative costs, treatment costs and facility costs (high dependency, ICU, neonatal 
ICU, ventilation, medications, dialysis and transfusions) (Simon, Gray & Duley, 2006). 
And seventh, implementing WHO guidelines and recommendations, which 
use evidence-based clinical criteria, will improve pre-eclampsia/eclampsia management.  
The most compelling strategy to address poor outcomes for patients presenting with pre-
eclampsia and eclampsia are criteria published in a 2000 Bulletin of the World Health 
Organization by Graham, W., et. al. A short and easy-to-follow set of criterion for the 
optimal management of eclampsia:  
 Senior Medical Staff takes responsibility of formulating a management plan for the 
patient.  
 Anti-hypertensive treatment is given to patients with severe hypertension.  
 The treatment and prophylaxis of seizures is with MgSO4 
 Respiratory rate and tendon reflexes are monitored when MgSO4 is used (to test for 
toxicity).  
 Antepartum/intrapartum fluid balance chart is maintained.  
 Hematological and renal investigations are done at least once: clotting time, platelet 
count, and urine albumin test.  
 Delivery is achieved within 12 hours of the first convulsion.  
 Monitoring of blood pressure and urine output continues for at least 48 hours after 
delivery (Graham, 2000). 
 
More importantly, these criteria were evaluated for use in a clinical setting in 
southwestern Nigeria in 2002-2003.  Original research conducted in the Federal Medical 
Centre in Abeokuta described results of a pre-test and post-test of implementation of the 
above criteria by clinical staff.  Researchers assessed quality of care before criteria were 
instated by a discreet audit of patient records for documentation of activities related to  
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Figure 4. Details of pre- and post-intervention assessment of 
Quality of Care and comparison of the care score of each 
criterion for the two phases.  
care and outcomes.  They then met with nursing staff to discuss their findings and 
institute the new criteria.  The second phase of the study which implemented the new 
criteria lasted for six months.  This study is remarkable because clinic staff identified a 
specific need for the provision 
of MgSO4 in the feedback 
session before implementation 
of Phase II.  Indicating 
awareness of the inadequacy 
prior to implementation of a 
protocol which called for 
MgSO4 use.  Also, adherence 
to the criteria was based on a 
score of one per unit criteria, if 
criteria were only partially 
fulfilled a half point was given.  
Significant to this study was the total care score prior to implementation for eclampsia of 
54.3% and 90% post implementation; Figure 4  
demonstrates percent change in the uptake and adherence to each criterion by clinic 
staff for care for eclamptic patients (Hunyinbo, Fawole, Sotilove, Otolorin, 2008).  
Other WHO generated resources for training health care providers and traditional 
birth attendants can be adapted to suit urban and rural Nigerians at different literacy 
levels and according to experience. These guides provide illustrations, definitions, risk 
factors, didactic exercises and checklists for understanding onset of disease (WHO, 2005; 





Management plan by 
senior medical staff   
81.8 100.0 1.0 (NS) 
Antihypertensive 
treatment in severe 
hypertension  
86.0 100.0 0.6 (NS) 
 
MgSO4 for seizure 
treatment and prophylaxis  
0 88.9 0.004 (S) 
Respiratory rate and 
tendon reflexes monitored 
while on MgSO4  
0 66.6 0.01 (S) 
Ante/intrapartum fluid 
balance chart 
81.8 100.0 1.00 (NS) 
Hematologic and renal 
investigation done at least 
once (clotting time, 
platelet count, urine 
Albumin)  
55.0 83.6 0.4 (NS) 
Delivery achieved within 
12 hours of first 
convulsion 
18.2 61.6 0.3 (NS) 
BP and urine output for at 
least 48 hours after 
delivery   
90.9 100.0 0.6 (NS) 
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WHO, 2008).  Traditional birth attendants can be taught how to administer basic 
antenatal testing as recommended by the WHO (blood pressure, urine tests for bacteria 
and protein, and blood tests for syphilis and anemia) and referral routes for women who 
need more specialized care.  Early recognition of the characteristics related to pre-
eclampsia and eclampsia is likely to hasten administration of the appropriate treatment 
regime.  Herein, engagement of the array of stakeholders previously mentioned is key to 
gain trust and buy-in for use and to determine functionality of such resources.  
 
Conclusions 
 Upwards of 10,000 women are dying from pre-eclampsia/eclampsia in Nigeria 
each year and the use of MgSO4 could cut this in half.  For each death it is estimated 
there are 30 cases of morbidity.  In the case of pre-eclampsia and eclampsia it is 
somewhat likely a woman will have hypertension after her pregnancy or later in life.  
Complications related to hypertension and history of pre-eclampsia/eclampsia includes 
cardiomyopathy, retinopathy, renal damage, and incidence of stroke and heart attack 
(Oyati, 2008).  This disease puts a tremendous strain on the public health status of the 
country, resulting in an array of economic consequences to the individual and society.   
 It has been established within this review that MgSO4 is not currently available in 
teaching hospitals and medical centers in all geographic regions in Nigeria.  Provision of 
essential medicine was established in the 1978 Alma Ata Declaration as one of eight key 
components of basic health care in article VII Primary Health Care (Laing, 2003).  
Evidence-based criteria for drug inclusion on the EML is that there must be public-health 
relevance, established efficacy, safety, and cost effectiveness.  Although MgSO4 is on the 
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Nigerian EML it is not on “The Primary Health Care List” or properly categorized on the 
“Products to be Stocked and Sold by Patent Medicine Dealers/vendors” list, nor is it 
available in village dispensaries (Federal MOH Abuja Nigeria 2003).  These failures to 
list appropriately are likely a primary cause of drug unavailability within the country.  
Health care providers of all types need access to therapeutics which offer the most 
favorable outcomes for their clients.  This includes traditional birth attendants who 
require training in recognizing pre-eclampsia, administration of MgSO4 and patient 
monitoring.  Also, women need access to facilities and providers that are both nearby 
their homes and adequately equipped to manage obstetric emergencies for optimal health 
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Appendix A 
Critical Reading of the Medical Literature: Format for Review of Articles 
 
 
1) What was the purpose of the study? 
2) List the study‟s hypothesis and comment on whether they are directly stated or 
implied. 
3) Basic description of study design: 
a. What kind of study was it 
b. Describe the study population (use of sampling, defined eligibility criteria, 
etc.) 
c. Identify potential problems with design (selection bias, inappropriate 
comparison groups, etc.) 
4) Describe the intervention(s) or treatment(s), if any: 
5) Data collection 
a. What was measured 
b. How and when were data collected? 
c. Identify any problems with data and data collection (factors measured, factors 
poorly measured, subjects lost to follow-up, etc.) 
6) Is the plan for data analysis clear and reasonable? 
7) Results: 
a. Discuss the presentation of the data (content and clarity of tables and text). 
b. List and discuss important result: 
c. Discuss the investigators‟ interpretations and conclusions: 
8) Overall critique of the study: 
a. Did the investigators accomplish what they set out to do? 
b. Summarize both successes/innovations and fatal flaws/major problems in 
design, methodology, or interpretations.   What would you do differently? 
9) Is the study relevant for clinical practice? 
10) Are the results generalizable? 
11) Overall summary rating of the paper 
3-4  Severe limitations in interpreting results of drawing conclusions 
5-6  Questionable confidence in results or conclusions 
7-8  Worth reading, but some limitations 
9-10 Outstanding contribution 
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Appendix B: Articles reviewed for management of pre-eclampsia/eclampsia in Nigeria, 2000- 2011. 
 
Source Location and type of study Management/therapy  Observation Outcomes 
Tukur, J., Muhammad, Z., 2010  Aminu Kano Teaching 
Hospital, North Central 
Nigeria.                              
Retrospective chart review of 
diazepam vs MgSO4.                
Jan 2002 - Dec 2004 and           
Jan 2005 - Dec 2007.                                        
N=131 
Diazepam compared to MgSO4 Maternal and perinatal  
mortality, APGAR scores @1 
and 5 minutes, toxic effects, 
delay at presentation and 
unbooked for ANC.  
Significant for: 38 tx w/ 
diazepam, 39% (15) died. 93 tx 
w/ MgSO4, 15% (14) died. 41 
babies‟ stillbirth. Total 29 
deaths: 25 delayed care; 26 had 
no ANC. 
Kullima, A.A., Kawuwa, M.B., 
Audu, B.M., Usman, H., 
Geidam, A.D., 2009 
Federal Medical Centre Nguru, 
Nguru State, Nigeria, Northeast 
Nigeria.                              
Retrospective chart review of 
eclampsia in a tertiary care 
unit.                                        
2003 - 2007.                                      
N=52  
Diazepam Maternal death, age, parity, 
education level, booking status, 
mode of delivery, time of onset, 
treatment for fits, GA at 
delivery, and fetal outcomes. 
224 dx eclampsia, 194 illiterate 
and 204 had no ANC. 52 
maternal deaths (46% of 
facility deaths), of maternal 
deaths 23 babies lived. Fit 
control in 47 using diazepam. 
Lack of ANC and EmOC. 
Okafor UV, 2009  Enugu, Nigeria. University of 
Nigeria Teaching Hospital.             
Central Nigeria           
Retrospective chart review of 
anesthetic management and 
perinatal outcomes.                         
1998-2006.                                      
N=196,  





Demographics, stillbirths, early 
neonatal deaths, maternal 
mortality and type of anesthesia 
administered. 
73 mothers w/ PE, 123 mothers 
with severe PE or eclampsia- 
all had cesarean;                            
157 delivered under general 
anesthesia (30 perinatal 
deaths), 34 spinal anesthesia (8 
perinatal deaths), 5 epidural (0 
deaths).                                  
154 >32 weeks. 38 26-
31weeks. Inadequate 
management of anesthesia to 
reduce PMR.  Use of MgSO4 
may have reduced cesarean rate 
by lowering incidence of 
eclampsia.                                  
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Okafor, U.V., and Efetie, R.E. 
2008 
Abuja, Nigeria, Central Nigeria                         
Retrospective chart review of 
eclampsia patients in the ICU.   
Nov 2001 - April 2005.                                            
n=38 
Diazepam and MgSO4 Patient demographics, booking 
status, parity and gestational 
age at delivery and at onset of 
seizures 
38 ICU admissions postpartum.  
20 onset antepartum, 6 
intrapartum and 12 postpartum.  
Age range 17-40.  23 
primigravida.  29 cesarean, 9 
vaginal.                                                  
37 diazepam 1 MgSO4. 
Antihypertensive was 
hydrallazine control.  11 
deaths, 17 ventilated from 
diazepam sedation. 
Igberase, G. O. and Ebeigbe, 
P.N. 2006 
Eku, Delta State, Nigeria. 
Southeastern Coast.                   
Ten year retrospective chart 
review of eclampsia outcomes 
in rural areas                                      
Jan 1994 - Dec 2003.                         
N = 123 
MgSO4 Age, parity, booking status, 
clinical presentation, maternal-
fetal outcomes. 
43% age 20-25, 59% 
primigravida, 86% unbooked, 
53% full term. 2.3% eclampsia 
in ten yrs. 19 maternal deaths, 
24 neonatal deaths. 82 
cesarean, 31 vaginal, 10 
assisted delivery. 12+ hrs from 
first seizure for 48% of the 
women to get EmOC.  
Untimely MgSO4 
administration negated 
protective effects.  
Melah, G.S., Massa, A.A., El-
Nafaty, A.U. 2005 
Gombe, Nigeria.                      
Rural eastern central Nigeria.                   
Retrospective chart review                                  
Jan 1997 - Dec 2000.           
N=438.  
Therapy was not specifically 
noted other than stating that 
MgSO4 is not available in the 
labor and delivery unit. 
Age, parity, booking status, and 
pregnancy outcomes  
3.7% dx eclampsia, 67.8% 
teen-aged, 79.8% primigravida. 
47 of 228 maternal deaths and 
157 neonatal deaths due to 
eclampsia. 91% women had 
warning signs. Supporting the 
hypothesis that ANC would 
have prevented mortality. 
 Ikechebelu, J.I., and Okoli, 
C.C. , 2002 
Nnamdi Azikiqe University 
Teaching Hospital, Nnewi, 
Southern Nigeria                       
Retrospective chart review         
Jan 1996-Decr 2000.                      
N=43.  
Diazepam for convulsions and 
hydrallazine for hypertension 
Dx of eclampsia, age, parity, 
booking status, time of onset,  
mode of delivery and 
outcomes.                                
.75% (43) incidence of 
eclampsia, 32.6% age 21-25, 
65% primigravida, 84% 
received no ANC and more 
likely to be eclamptic 
antepartum (55.8%). 86% 
cesarean.   9.3% maternal 
deaths.  16.3% neonatal deaths.   
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Onah, H.E.; Iloabachie, G.C.; 
2002 
University of Nigeria Teaching 
Hospital, Enugu, south central 
Nigeria.                          
Prospective case-control study.                                      
May 1995-June 2000.                    
N=749.  
Conservative management of 
pre-eclampsia: bed rest, alpha-
methyldopa or hydrallazine as 
anti-hypertensive.          
Diazepam for seizures, 
Compared early onset (case) to 
late on-set controls for 
outcomes using conservative 
management. Other variables: 
age, parity, booking status, 
SES, family history of 
hypertension and other medical 
disorders. 
175 cases: onset of disease 
before 30 weeks gestation;           
574 controls: onset after 30 
weeks. Cases: 91 pure pre-
eclampsia, 84 superimposed 
pre-eclampsia; 21 developed 
eclampsia and 7 died.         
Controls: 98 developed 
eclampsia,  7 died.                                                 
Cases: avg 31 yrs-old, 
primigravida, 68% booked, 
52% >$100/month, 52% 
tertiary education, 64% no 
family hx of hypertension, 68% 
bp≥170/100, 92% no other 
medical disorders.                                                 
Controls: avg 29 yrs-old, 
primigravida, 66% booked, 
37% ≥$100/month, 46% 
tertiary education, 73% no 
family hx of hypertension, 57% 
bp≥170/100, 94% had no other 
medical disorders.                      
 
